Details for New Drug Application (NDA): 022224

✉ Email this page to a colleague

NDA 022224 describes TRILIPIX, which is a drug marketed by Abbvie and is included in one NDA. It is available from one supplier. There is one patent protecting this drug and two Paragraph IV challenges. Additional details are available on the TRILIPIX profile page.

The generic ingredient in TRILIPIX is choline fenofibrate. There are one hundred and two drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the choline fenofibrate profile page.

Summary for 022224

Tradename:	TRILIPIX
Applicant:	Abbvie
Ingredient:	choline fenofibrate
Patents:	1

Suppliers and Packaging for NDA: 022224

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
TRILIPIX	choline fenofibrate	CAPSULE, DELAYED RELEASE;ORAL	022224	NDA AUTHORIZED GENERIC	Amneal Pharmaceuticals of New York LLC	0115-1554	0115-1554-10	90 CAPSULE, DELAYED RELEASE in 1 BOTTLE (0115-1554-10)
TRILIPIX	choline fenofibrate	CAPSULE, DELAYED RELEASE;ORAL	022224	NDA AUTHORIZED GENERIC	Amneal Pharmaceuticals of New York LLC	0115-1555	0115-1555-10	90 CAPSULE, DELAYED RELEASE in 1 BOTTLE (0115-1555-10)

Profile for product number 001

Active Rx/OTC/Discontinued:	DISCN	Dosage:	CAPSULE, DELAYED RELEASE;ORAL			Strength	EQ 45MG FENOFIBRIC ACID
Approval Date:	Dec 15, 2008	TE:		RLD:	Yes
Patent:	⤷ Get Started Free	Patent Expiration:	Jan 7, 2025	Product Flag?		Substance Flag?	Y	Delist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:	DISCN	Dosage:	CAPSULE, DELAYED RELEASE;ORAL			Strength	EQ 135MG FENOFIBRIC ACID
Approval Date:	Dec 15, 2008	TE:		RLD:	Yes
Patent:	⤷ Get Started Free	Patent Expiration:	Jan 7, 2025	Product Flag?		Substance Flag?	Y	Delist Request?

Expired US Patents for NDA 022224

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	TRILIPIX	choline fenofibrate	CAPSULE, DELAYED RELEASE;ORAL	022224-001	Dec 15, 2008	⤷ Get Started Free	⤷ Get Started Free
Abbvie	TRILIPIX	choline fenofibrate	CAPSULE, DELAYED RELEASE;ORAL	022224-002	Dec 15, 2008	⤷ Get Started Free	⤷ Get Started Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.